Primary Ipilimumab / Nivolumab immunotherapy followed by adjuvant Nivolumab in locally advanced or oligometastatic melanoma: preliminary results


The aim of neo-adjuvant therapy in locally advanced or oligometastatic melanoma is to facilitate radical resection, improve outcomes and undertake research to identify biomarkers of response and resistance.
Recently, pathological response has been indicated as a surrogate of survival.

Researchers have investigated the efficacy of Ipilimumab ( Yervoy ) / Nivolumab ( Opdivo ) combination as primary treatment of locally advanced or oligometastatic melanoma patients, within an open label, single arm, two centres study.

Treatment schedule consisted of 4 neoadjuvant cycles of Ipilimumab 1 mg/kg and Nivolumab 3 mg/kg every 3 weeks, followed by surgery and adjuvant Nivolumab 480 mg every 4 weeks for 6 cycles.

Primary objective is pathological complete remission ( pCR ) rate. Secondary objectives were: safety, feasibility and efficacy; health related quality of life; identification of molecular and immunological biomarkers of response and resistance ( somatic genetic drivers, tumor mutational burden [ TMB ], mutational signatures, predicted neoantigens, germline HLA typing, somatic HLA mutations and liquid biopsy ); degree of immune activation; evaluation of microbioma.

From March 2019, 26 out of 35 patients were enrolled. In the ITT population ( 22 patients ), 21 patients were stage III and 1 stage IV-M1b cutaneous melanoma; 17 patients concluded neoadjuvant therapy and received surgery; 4 patients concluded the adjuvant treatment.

Pathologic complete response ( pCR ) was reached in 9/17 ( 52% ), pathological partial remission in 4/17 ( 24% ) and pathological no response ( pNR ) in 4/17 ( 24% ) patients.

With a median follow-up of 5 months, all patients are alive; one, with pNR at surgery, relapsed during adjuvant phase.

In the neoadjuvant phase 4 patients ( 18% ) developed G3-4 adverse events: 2 transaminitis, 1 myocarditis and 1 asyntomatic CPK increase after 4, 3 and 2 cycles; 3 of them underwent to surgery after toxicity resolution.
No G3-4 adverse events were observed during adjuvant phase.

In conclusion, primary Ipilimumab / Nivolumab is effective and feasible, showing high pCR rate. Toxicity was superimposable to that already observed with this schedule.
Longer follow-up is needed to assess a correlation between pathological response and survival. ( Xagena )

Source: European Society for Medical Oncology ( ESMO ) Virtual Meeting, 2020

XagenaMedicine_2020



Indietro

Altri articoli

Data from the five-year analysis featuring extended follow-up from the phase III COMBI-AD study have confirmed that 12 months of...


There has been an only indirect comparison between Pembrolizumab ( Keytruda ) and Pembrolizumab plus chemotherapy in patients with non-small...


The ALEX study has demonstrated significantly improved progression-free survival ( PFS ) with Alectinib ( Alecensa ) versus Crizotinib (...


In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for...


The mRNA-1273 vaccine for SARS-CoV-2 is tolerable and immunogenic in older adults. Data on prolonged immunogenicity and effectiveness in preventing severe...


The European Commission ( EC ) has granted conditional marketing authorization to Ayvakyt ( Avapritinib ) as a monotherapy for...


The FDA ( U.S. Food and Drug Administration ) has approved Ayvakit ( Avapritinib ) for the treatment of adults...


The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...


The coronavirus disease 2019 ( COVID-19 ) virus, emerged in December 2019, has spread rapidly, with cases now confirmed in...